氯喹、羟氯喹与听力损失：系统性红斑狼疮患者的一项研究。
Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients.
机构信息
Department of Otorhinolaryngology-Head and Neck Surgery, Federal University of Parana, and Mackenzie Evangelical School of Medicine-Parana, Curitiba, Brazil.
Rheumatology Clinic, Mackenzie Evangelical University Hospital, Mackenzie Evangelical School of Medicine -Parana, Curitiba, Brazil.
出版信息
Laryngoscope. 2021 Mar;131(3):E957-E960. doi: 10.1002/lary.28873. Epub 2020 Jun 30.
OBJECTIVES/HYPOTHESIS: Antimalarial drugs (chloroquine and hydroxychloroquine) are widely used for the treatment of systemic lupus erythematosus (SLE). However, these drugs may have side effects such as hearing loss. This study aimed to describe the hearing function in SLE patients using antimalarials. Secondarily, this study aimed to investigate whether SLE causes hearing loss and if there are any serological or clinical aspects of this diseases associated with inner ear damage.
STUDY DESIGN
Cross-sectional study.
METHODS
This study included 84 individuals (43 SLE patients and 41 controls) with audiometry and tympanometry tests. Epidemiological, clinical, serological, and treatment profiles of SLE patients were extracted from the charts.
RESULTS
SLE patients had more sensorineural hearing loss than controls (23.2% vs. 0; P = .001). Pure-tone averages in SLE patients using antimalarials and not using antimalarials were similar (8.75 vs. 8.75; P = .63). At 8,000 Hz, antimalarial dug nonusers performed worse than users (10.00 vs. 22.50; P = .03). Tympanometry was normal in all participants. SLE serological and clinical profiles in patients with and without hearing loss were the same (all P = nonsignificant).
CONCLUSIONS
There is a high prevalence of hearing loss in SLE that is not affected by antimalarial drug use.
LEVEL OF EVIDENCE
3b Laryngoscope, 131:E957-E960, 2021.
目的/假设：抗疟药物（氯喹和羟氯喹）被广泛用于治疗系统性红斑狼疮（SLE）。然而，这些药物可能有副作用，如听力损失。本研究旨在描述使用抗疟药的 SLE 患者的听力功能。其次，本研究旨在调查 SLE 是否会导致听力损失，以及这种疾病是否存在任何与内耳损伤相关的血清学或临床方面。
研究设计
横断面研究。
方法
本研究纳入了 84 名受试者（43 名 SLE 患者和 41 名对照者），进行了听力测试和鼓室压测试。从病历中提取了 SLE 患者的流行病学、临床、血清学和治疗概况。
结果
SLE 患者的感音神经性听力损失多于对照组（23.2% vs. 0；P = 0.001）。使用和未使用抗疟药的 SLE 患者的纯音平均值相似（8.75 vs. 8.75；P = 0.63）。在 8000Hz 时，抗疟药非使用者的表现不如使用者（10.00 vs. 22.50；P = 0.03）。所有参与者的鼓室压测试均正常。有听力损失和无听力损失的 SLE 患者的血清学和临床特征相同（所有 P = 非显著）。
结论
SLE 患者的听力损失发生率较高，且不受抗疟药物使用的影响。
证据水平
3b 喉镜，131：E957-E960，2021 年。
Zotero 插件